Loading clinical trials...

Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT). | Clinical Trials | Clareo Health

RECRUITINGPHASE2

Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).

Brachytherapy Fractionation Individualized by Treatment Feasibility in Cervical Cancer: Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).

NCT07022470•Stanford University

View on ClinicalTrials.gov

Summary

This is a prospective non-randomized clinical trial to evaluate the feasibility of 3 fraction versus a standard 4 fraction high dose rate brachytherapy regimen in patients with locally advanced cervical cancer.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically documented malignancy of the cervix and planned to receive brachytherapy as part of definitive treatment.
•ECOG performance status of 0-2
•Age ≥ 18 years old.
•Ability to understand and the willingness to provide written informed consent.

Exclusion Criteria

•Contraindication to receiving radiotherapy as determined by treating radiation oncologist.
•Contraindication to receiving MRI.
•Prior radiation to the pelvis \> 3 months ago
•Age \< 18 years old.
•Pregnant or breast-feeding

Locations (1)

Stanford University

Palo Alto, California, United States

Key Dates

Start Date

June 3, 2025

Primary Completion Date

June 1, 2028

Completion Date

June 1, 2028

Last Updated

June 15, 2025

Enrollment

ESTIMATED participants

Conditions

Cervical Cancers

Interventions

3-Fraction HDR Brachytherapy

RADIATION

4-Fraction HDR Brachytherapy

RADIATION

Contacts

Alyssa Alyssa

CONTACT

(650) 498-5271 ayauger@stanford.edu

Jillian Skerchak

CONTACT

(650) 721-4072 jskerch1@stanford.edu

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

NCT07038369

Advanced Solid TumorsBreast Cancer+25 more

View study

NOT_YET_RECRUITINGPHASE2

Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer

NCT07244965

LOCALLY ADVANCED CERVICAL CANCERS

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 15, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).

Inclusion Criteria

Exclusion Criteria

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer

Effects of Health Education on Knowledge, Attitude and Screening for Cervical Cancer in Women

Quality Control of Colposcopy Application

Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment

A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)